Table 2.
Efficacy of peptide receptor radionuclide therapy in patients with metastatic MTCa
| Reference (Publish Year) | Country | N | Sex | Age | Site of metastasis | Prior treatment | Ligand (Radionuclide Chelator Peptide) | Cumulative activity (GBq) | Response criteria | TTP in SD (month) | Follow-Up duration (months) | Response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ksz M et al. (2014) [43] | Switzerland | 1 | NA | NA | NA | TT/ND/C | 90Y-DOTA-TOC | 5.65 | Biochemical | NA | 3 | PD |
| RECIST | PD | |||||||||||
| EORTC | PD | |||||||||||
| Bertagna F et al. (2009) [44] | USA | 1 | M | 74 | B/M/ H | TT/ND/RF | 90Y-DOTA-TOC | 9.01 | Biochemical | NA | 7 | SD |
| RECIST | NA | SD | ||||||||||
| WHO | NA | SD | ||||||||||
| EORTC | NA | PR | ||||||||||
| Iten F et al. (2007) [45] | Switzerland | 31 | F/M: 10/21 | Mean: 56.7 (24.076.9) | NA | TT/ND/C/EBR | 90Y-DOTA-TOC | 1.729.6 | Biochemical | NA | 15.7 (1.4_107) | 9R, 22NR |
| Bodei L et al. (2004) [46] | Italy | 21 | F/M: 8/13 | Median: 53 (3178) | Lu/Li/B/M | TT/ND/C/EBR/BT | 90Y-DOTA-TOC | 7.519.2 | Biochemical | NA | 40 | 3SD, 12PD, 5PR, 1CR |
| SWOG | NA | 12SD, 7PD, 2CR | ||||||||||
| Gao ZR et al. (2004) [47] | China | 1 | M | 58 | Lu/ M | NA | 90Y-DOTA-TOC | 3.33 | Biochemical | 6 | 10.5 | PR |
| WHO | SD | |||||||||||
| Waldherr C et al. (2001) [27] | Switzerland | 12 | F/M: 5/7 | Median: 60 (24_72) | NA | TT/ND/C/EBR/BT/EN | 90Y-DOTA-TOC | 1.7_14.8 | WHO | 10 (3_14) | 15 (1_31) | 5SD, 7PD |
| Otte A et al. (1999) [48] | Switzerland | 2 | F | 65 | NA | NA | 90Y-DOTA-TOC | 9.25_9.62 | WHO | NA | 24 | 2SD |
| Bilgic, S et al. (2020) [49] | Turkey | 19 | F/M: 6/13 | 32_87 | Lu/Li/B/M | TT/ND/C | 177Lu-DOTATATE | 6.5_52.3 | Biochemical | NA | NA | 7SD, 8PR, 4PD |
| Imaging | 15SD, 2PR, 2PD | |||||||||||
| Cinkir, H. Y et al. (2020) [31] | Turkey | 3 | M | Median: 53 (38,59) | Lu/B/M | TT/ND/C/EBR | 177Lu-DOTATATE | 14.8_44.4 | EORTC | 37.3 (17.6_56.9) | 24.2 (0_48.8) | 3SD |
| Parghane, R. V et al. (2020) [50] | India | 43 | F/M: 8/35 | Median: 48 (25,80) | Lu/Li/B/M | TT/ND/C/EBR | 177Lu-DOTATATE | 5.55_33.3 | Biochemical | 24 (15.1_32.9) | 26 (16.6_35.3) | 5CR, 4SD, 13PR, 21PD |
| RECIST | 22SD, 4PR, 17PD | |||||||||||
| Makis W et al. (2015) [51] | Canada | 2 | NA | Median: 56.5 (38,75) | B/M | TT/ND | 177Lu-DOTATATE | 22.2 | Biochemical | NA | 9.5 (9,10) | 1PR, 1PD |
| WHO | 2SD | |||||||||||
| Vaisman F et al. (2015) [52] | Brazil | 7 | NA | Median: 35.8 (20_54) | NA | NA | 177Lu-DOTATATE | 29.6 | RECIST | NA | 12 | 3PR, 3SD, 1PD |
| Soydal et al. (2014) [53] | Turkey | 2 | F/M | Median: 41 | Lu/Li | TT/ND/EBR | 177Lu-DOTATATE | 29.6 | RECIST | NA | 6weeks After fourth cycle | 2SD |
| Beukhof, C et al. (2019) [54] | Netherlands | 10 | F/M: 6/4 | Median: 62 (1975) | NA | NA | 177Lu-octreotide | 27.8_29.6 | Biochemical | 8.4 (3.6_144) | 16.88 (4.8_144) | 3SD, 4PR, 3PD |
| RECIST | 4SD, 6PD | |||||||||||
| Mathew, D et al. (2018) [55] | India | 2 | NA | NA | NA | NA | 177Lu-octreotide | NA | Imaging | NA | 7weeks After last cycle | 2SD |
| Pasieka JL et al. (2004) [56] | Canada | 1 | M | 46 | M | TT/ND/C | 1111n-Octerotide | 11.954 | Biochemical | NA | 9 | PD |
| SWOG | ||||||||||||
| Valkema R et al. (2002) [39] | Netherlands | 5 | NA | Median: 57.4 (27.7_77.4) | B/Lu | TT/ND/C/EBR/BT | 1111n-Octerotide | 25.14_87.28 | Biochemical | NA | 7.8 (2.76_26.8) | 2SD, 3PD |
| SWOG | 7.8 (2.76_26.8) | 3SD, 2PD | ||||||||||
| Caplin M et al. (2000) [57] | Poland | 1 | F | 46 | NA | NA | 1111n-Octerotide | 11.4 | Biochemical | NA | NA | CR |
| Krenning E et al. (1999) [40] | Netherlands | 3 | NA | NA | NA | NA | 1111n-Octerotide | NA | Imaging | NA | 24 | 1SD, 2PD |
| Buscombe JR et al. (2003) [58] | UK | 2 | NA | Median: 52 (4658) | NA | NA | 1111n-pentetreotide | 25_75 | RECIST | NA | 27.5 (22,33) | 2CR |
| Hayes AR et al. (2019) [59] | UK | 9 | NA | NA | NA | NA | 90Y-DOTATATE and/or 177Lu-DOTATATE | NA | Biochemical | 14 (820) | NA | 6PR, 3PD |
| Puranik A et al. (2019) [60] | India | 28 | F/M: 14/14 | Mean: 47.9 (26_72) | NA | TT/ND/C/EBR | 90Y-DOTATATE and 177Lu-DOTATATE | NA | EORTC | NA | 36 | 17SD |
| 72 | 5PR | |||||||||||
| 24 | 6PD | |||||||||||
| Budiawan H et al. (2013) [6] | Germany | 7 | F/M: 3/4 | Median: 66.5 (21_68) | Lu/Li/B | TT/ND/EBR/ | 90Y-DOTATATE and 177Lu-DOTA-TATE | NA | EORTC | NA | 50.4 (34.866) | 4SD, 1PD, 1PR |
| Scalorbi F et al. (2017) [42] | Italy | 7 | F/M: (4/3) | NA | NA | NA | NA | NA | NA | NA | NA | 5SD, 2PD |
aAbbreviations: NA Not Available, MTC Medullary Thyroid Carcinoma, TTP Time To Progression
Metastatic Site: A Adrenal, Li Liver, Lu Lung, B Bone, M Mediastinum
Prior treatments: TT Total Thyroidectomy, ND Node Dissection, EBR External Beam Radiation, C Chemotherapy, BT Biotherapy with Octreotide, LITT Laser Induced Thermotherapy, REDIFF Redifferentiation Using Roaccutane
Response: CR Complete Response, PR Partial Remission, SD Stable Disease, PD Progressive Disease, MR Minor Remission